Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
04/26/20176:48PMPRNUSNeurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering
Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering PR Newswire SAN DIEGO, April 26, 2017 SAN DIEGO, April 26, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25% convertible... More...>>
04/25/20174:01PMPRNUSNeurocrine Announces Proposed Convertible Senior Notes Offering
Neurocrine Announces Proposed Convertible Senior Notes Offering PR Newswire SAN DIEGO, April 25, 2017 SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible... More...>>
04/21/20176:00AMPRNUSNeurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology...
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations PR Newswire SAN DIEGO, April 21, 2017 SAN DIEGO... More...>>
04/11/20175:37PMPRNUSNeurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults w...
Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia) Provides significant and rapid reduction in involuntary movements with simple once-daily dosing Enables treatment of TD with commonly prescribed psychiatric... More...>>
04/11/20174:52PMPRNUSNeurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults w...
Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) Provides significant and rapid reduction in involuntary movements with simple once-daily dosing Enables treatment of TD with commonly prescribed psychiatric medication... More...>>
04/07/20178:00AMPRNUSAbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual...
AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids - Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids... More...>>
03/21/20178:59AMPRNUSNeurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA...
Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia - Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA - INGREZZA... More...>>
02/14/20174:01PMPRNUSNeurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 INGREZZATM New Drug Application PDUFA Action Date of April 11, 2017 Acquired U.S. Rights to Opicapone for Parkinson's Disease Elagolix New Drug Application Submission for Endometriosis Expected in Third Quarter of 2017 Two Phase... More...>>
02/09/20174:01PMPRNUSNeurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease ONGENTYS® (opicapone) Approved in Europe in June 2016 Neurocrine to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm... More...>>
02/07/20171:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results Conference Call and Webcast Scheduled for Tuesday, February 14, 2017 PR Newswire SAN DIEGO, Feb. 7, 2017 SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>>
01/17/20174:01PMPRNUSNeurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Touret...
Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects Company to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT PR Newswire SAN DIEGO, Jan... More...>>
01/06/20178:30AMPRNUSNeurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer PR Newswire SAN DIEGO, Jan. 6, 2017 SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced... More...>>
01/05/20174:01PMPRNUSNeurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT PR Newswire SAN DIEGO, Jan. 5, 2017 SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:... More...>>
01/03/20171:00PMPRNUSNeurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 9, 2017 PR Newswire SAN DIEGO, Jan. 3, 2017 SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
12/21/20164:01PMPRNUSNeurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down Will Continue to Support Company Over Extended Transition Period Through End of 2017 PR Newswire SAN DIEGO, Dec. 21, 2016 SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company... More...>>
12/07/20161:00PMPRNUSNeurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference
Neurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference Live Audio Webcast will be on December 14, 2016 PR Newswire SAN DIEGO, Dec. 7, 2016 SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President... More...>>
12/05/20165:30PMPRNUSNeurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the A...
Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology New One Year Safety and Efficacy Data of INGREZZA in Tardive Dyskinesia Patients PR Newswire SAN DIEGO, Dec. 5, 2016 SAN DIEGO, Dec. 5, 2016 /PRNewswire/... More...>>
12/01/201610:00AMGLOBENeurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Dec. 01, 2016 (GLOBE NEWSWIRE) -- What:  Neurocrine Biosciences (Nasdaq:NBIX), a company that discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders... More...>>
11/29/20164:15PMPRNUSNeurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatmen...
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia Advisory Committee Meeting Scheduled for February 16, 2017 PR Newswire SAN DIEGO, Nov. 29, 2016 SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:... More...>>
11/21/20165:00PMPRNUSNeurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference Live Audio Webcast will be on November 30, 2016 PR Newswire SAN DIEGO, Nov. 21, 2016 SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20170428 06:20:47